A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
for Recurrent Langerhans Cell Histiocytosis
104 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 180 Days - 22
Code: NCT05828069·Phase 2·Recruiting